Hemolytic uremic syndrome

Common Name(s)

Hemolytic uremic syndrome

Hemolytic uremic syndrome (HUS) is a condition in which red blood cells are abnormally destroyed, leading to a decreased red blood cell count (anemia) and destruction of the platelets (thrombocytopenia). Platelets are found circulating in the blood and are involved in clot formation to stop bleeding. HUS is most often caused by an infection of a certain strain of E. coli. An individual is likely to ingest E. coli, a bacterium, when eating undercooked, spoiled, or contaminated food or drinking contaminated water. Children ages 2 to 14 are most commonly affected. In adults, other causes of HUS are medications, other infections, and genetic inheritance (atypical hemolytic uremic syndrome).

HUS is often found after symptoms of bloody diarrhea and abdominal pain. Symptoms of HUS include paleness, fatigue, passing only small amounts of urine, bloody urine, stomach pain, swelling, vomiting, easy bruising, small amounts of bleeding from the mouth and nose, and fever. The debris from destroyed red blood cells in HUS can clog or damage the tiny blood vessels in the kidney, which is the organ that filters blood and produces urine. Kidney failure may occur and is a feared complication of this condition.

Diagnosis of HUS is usually made using a blood test to look at potential red blood cell damage, a urine test, and a stool test for bacteria. HUS is treated in a hospital and may involve fluid replacement, an injection of more red blood cells and/or platelets, injection of plasma (the liquid part of blood), and possibly kidney dialysis if the kidney can no longer filter blood. If you or a loved one has been diagnosed with HUS, talk to your doctor about the most current treatment options. Support groups are available for resources and more information.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hemolytic uremic syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hemolytic uremic syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Hemolytic uremic syndrome" returned 463 free, full-text research articles on human participants. First 3 results:

[Hemolytic-uremic syndrome (HUS) in children at the University Hospital Center in Dakar: about four cases].
 

Author(s): Aliou Thiongane, Aliou Abdoulaye Ndongo, Idrissa Demba Ba, Djibril Boiro, Papa Moctar Faye, Younoussa Keita, Aïssatou Ba, Djeynaba Fafa Cissé, Idrissa Basse, Lamine Thiam, Indou Déme Ly, Babacar Niang, Abou Ba, Amadou Lamine Fall, Saliou Diouf, Ousmane Ndiaye, Mamadou Ba, Mamadou Sarr

Journal:

 

Hemolytic-uremic syndrome (HUS) is a common cause of organic acute renal failure (ARF) in children. It is a progressive complication of acute gastroenteritis (AGE), especially caused by Escherichia coli in children. This study aimed to describe the clinical, therapeutic and evolutionary ...

Last Updated: 19 Sep 2016

Go To URL
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea.
 

Author(s): Hae Il Cheong, Sang Kyung Jo, Sung Soo Yoon, Heeyeon Cho, Jin Seok Kim, Young Ok Kim, Ja Ryong Koo, Yong Park, Young Seo Park, Jae Il Shin, Kee Hwan Yoo, Doyeun Oh

Journal: J. Korean Med. Sci.. 2016 Oct;31(10):1516-28.

 

Atypical hemolytic uremic syndrome (aHUS) is a rare syndrome characterized by micro-angiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The major pathogenesis of aHUS involves dysregulation of the complement system. Eculizumab, which blocks complement C5 activation, ...

Last Updated: 23 Aug 2016

Go To URL
Successful Renal Transplantation in a Patient with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab in China.
 

Author(s): Ze-Jia Sun, Xin Du, Lu-Lu Su, Xiao-Dong Zhang, Yong Wang, Liang Ren, Wei Wang

Journal: Chin. Med. J.. 2016 Jun;129(11):1379-81.

 

Last Updated: 27 May 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Hemolytic uremic syndrome" returned 54 free, full-text review articles on human participants. First 3 results:

A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome.
 

Author(s): Borja Quiroga, Alberto de Lorenzo, Cristina Vega, Fernando de Alvaro

Journal:

 

BACKGROUND Recent advances in the treatment of atypical hemolytic-uremic syndrome (aHUS) have resulted to better long-term survival rates for patients with this life-threatening disease. However, many questions remain such as whether or not long-term treatment is necessary in some ...

Last Updated: 15 Dec 2016

Go To URL
Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review.
 

Author(s): Clemence Deville, Cyril Garrouste, Paul Coppo, Bertrand Evrard, Alexandre Lautrette, Anne Elisabeth Heng

Journal: Medicine (Baltimore). 2016 Sep;95(39):e5007.

 

Antifactor H antibody (anti-CFHAb) is found in 6% to 25% cases of atypical hemolytic uremic syndrome (aHUS) in children, but has been only exceptionally reported in adults. There is no consensus about the best treatment for this type of aHUS. We report the case of an adult patient ...

Last Updated: 30 Sep 2016

Go To URL
Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome.
 

Author(s): Umut Kasapoğlu, Çaglar Ruhi, Murat Tuğcu, Başak Boynueğri, İzzet Titiz, Veysel Sabri Hançer, Süheyla Apaydın

Journal:

 

Atypical hemolytic uremic syndrome (aHUS) is a very rare disease, which presents with microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Progression to end-stage renal disease (ESRD) from acute kidney injury is observed in 60% of aHUS cases. The prognosis ...

Last Updated: 1 Dec 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry
 

Status: Recruiting

Condition Summary: Atypical Hemolytic-Uremic Syndrome

 

Last Updated: 17 Feb 2017

Go to URL
Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
 

Status: Not yet recruiting

Condition Summary: Atypical Hemolytic Uremic Syndrome (aHUS)

 

Last Updated: 24 Apr 2017

Go to URL
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS
 

Status: Recruiting

Condition Summary: Atypical Hemolytic Uremic Syndrome

 

Last Updated: 20 Sep 2016

Go to URL